Isis Optimistic on Pipeline, Myrexis Dissolves Itself: Healthcare Business Recap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Isis Pharmaceuticals (NASDAQ:ISIS) points to the optimism attending its antisense platform, along with a strong pipeline which includes its cholesterol treatment Kynamro that is expected to win FDA approval early in 2013, as the reason for its upgrade to Outperform on valuation at Cowen. Shares skyrocketed Friday in response.

Iridex Corporation (NASDAQ:IRIX) has reached a worldwide patent licensing agreement which will permit Quantel Medical to market and to display the former’s MicroPulse tech.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Insulet Corporation (NASDAQ:PODD) moved up on the day even though the company posted mixed third quarter results Thursday. Revenue jumped by 22 percent year-over-year, and investors are concentrating on its pipeline, among which includes its OmniPod insulin pump that currently awaits FDA approval. Barrington expects that approval should come within 90 days.

Myrexis (NASDAQ:MYRX) reports that its Board of Directors has opted to dissolve the company and liquidate its assets, upon shareholder approval. The firm intends to distribute all available cash, except such as is needed for paying or making reasonable provision for known and potential liabilities plus other obligations of the firm.

Don’t Miss: Who Will This Patent Troll Target Next?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business